Trial Profile
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ADMYRE
- Sponsors PharmaMar
- 01 Sep 2019 Results efficacy and safety of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma, published in the Annals of Hematology.
- 11 Dec 2018 The Australian Regulatory Agency (TGA) has informed STA that Aplidin (plitidepsin) has been approved for the treatment of multiple myeloma in combination with dexamethasone.
- 11 Dec 2018 Professor Jeff Szer, was the Australian principal investigator, according to a PharmaMar media release